MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.46
-0.07
-0.93%
After Hours: 7.46 0 0.00% 16:30 01/17 EST
OPEN
7.61
PREV CLOSE
7.53
HIGH
7.73
LOW
7.41
VOLUME
341.32K
TURNOVER
--
52 WEEK HIGH
19.75
52 WEEK LOW
5.10
MARKET CAP
338.94M
P/E (TTM)
-3.4084
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTMX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTMX News

  • CytomX Therapeutics Announces New Employment Inducement Grants
  • GlobeNewswire.2d ago
  • The CytomX Therapeutics (NASDAQ:CTMX) Share Price Is Down 45% So Some Shareholders Are Getting Worried
  • Simply Wall St..12/31/2019 14:07
  • CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook
  • GlobeNewswire.12/19/2019 13:03
  • CytomX Therapeutics Announces New Employment Inducement Grants
  • GlobeNewswire.12/17/2019 21:03

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
More

Webull offers CytomX Therapeutics Inc (CTMX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.